Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Marcum Microcap Conference 2013
24 slides from Biorestorative Therapies's conference presentation, May 30, 2013
Slide 1: BioRestorative Therapies, Inc.
bionestoreitins therapies BIORESTORATIVE THERAPIES, INC. Mark Weinreb, CEO OTCBB: BRTX biorestorative.com May 2013 bi orestordire
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements" within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. {the “Company”) to develop its adult stem cell business, the future of regenerative medi
Slide 3: Investment Highlights
gam /nvestment Highlights e BioRestorative Therapies (“BRT”) is a biotechnology company that develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments e Focused on 3 Programs: — Bul
Slide 4: brtxDISC Overview
mum DItxDISC™ Overview e brtxDISC™ (Disc Implanted Stem Cells) Program Non-surgical cellular, regenerative therapy for treatment and relief of bulging and herniated discs Utilizes autologous stem cells to repair damaged tissue, within the disc, through regenerative medicine ¢ Developed IP for cultur
Slide 5: brtxDISC Target Markets
brtxDISC Target Markets Discectomy- . brt, Bulge/HNP SC biorestordtlve
Slide 6: brtxDISC Proprietary Approach
game OrtxDISC™ Proprietary Approach | Cell Culturing | Selects mesenchymal stem cells (MSCs) that can survive in low oxygen (hypoxic) environment. | Cell Delivery | MSC cells are injected into posterior disc annulus using the brtxDISC™ cell delivery device allowing for precise delivery to the damage
Slide 7: brtxDISC Cell Delivery Device
brtxDISC™ Cell Delivery Device Patent-pending Cell Delivery Device Recurved super elastic delivery Cannulaallows cell delivery to internal disc sites, including those obstructed by outlying bone andnerve structures Integrated hub systemincludes Needle-to-Cannula anti-rotation features plus a linear
Slide 8: brtxDISC Process Overview
ma DtxDISC™ Process Overview \ Physician purchases collection/delivery device kit atient receives cells brtxDISC™ Delivery Device in physician’s office Physician collects patient cell sample BRT sends therapeutic Physician sends cells/dose back to patient’s cells to BRT for physician lab culturing
Slide 9: brtxDISC Market Size & Costs
mums DItxDISC™ Market Size & Costs Annual brtxDISC™ Procedure Incidence Surgical Cost (Estimated Sevneerer (U.S.) Cost) Spinal Fusion 300,000 $75-100K $18K $57-82K lise 200,000 $35-50K $18k $17-32K Replacement is Discectomy 200,000 $20-50K $18K $2-32K ¢ Surgical procedures are typically followed by
Slide 10: brtxDISC MRI Results
mae OrtxDISC™ MRI Results % 42y/o Male: Annular tear at L5-S1 noted on 2003 MRI and radiculopathy diagnosed. 2007 MRI showed a mild L5-S1 disc bulge. » Treated in Physician’s Office : 5 month follow-up MRI showed complete resolution of the L5-S1 disc bulge on both sagittal and axial slices with some
Slide 11: brtxDISC Development Path
mam DrtxDISC™ Development Path GOAL Ph.t Ph. Ph.ill Potential (ae J 2014- toBypass | 2014 2016 Completed CONSERVATIVE PATH Ph. Ph. Il Ph. lt 2013- 2014- 2016- | }\ 2014 Il 2015 Il 2018 | Completed biorestordtlve 1
Slide 12: ThermoStem Overview
uu PhermoStem® Overview ¢ Potential allogeneic brown fat stem cell treatment for metabolic disorders, primarily targeting Type 2 diabetes & obesity — “Good Fat” (brown adipose tissue) vs. “Bad Fat” (white adipose tissue) — Initial non-clinical research indicates that brown fat is present in the huma
Slide 13: Brown Fat Overview
man Grown Fat Overview “One of the most powerful organs in the body....Since it consumes both glucose and fatty acids, it is possible we could utilize brown fat to treat obesity and metabolic dysfunction seen in diabetes and hyperlipidemia. ” - Aaron M. Cypress. M.D.,. Ph.D.. Joslin Diabetes Center
Slide 14: ThermoStem Advantage
mae ThermoStem® Advantage BRT is developing a novel cellular therapy, using brown fat stem cells, to treat metabolic disorders and obesity — Strong IP BRT has access to human brown fat depots for research and clinical development — Collected over 100 specimens of human brown fat Identified first ste
Slide 15: Brown Fat Cells Implanted in a Biological Scaffold
| Brown Fat Cells Implanted in a Biological Scaffold Cell delivery method incorporates subcutaneous implant of decellularized scaffold containing brown fat 15
Slide 16: Pre-Clinical — Glucose/Weight
Pre-Clinical — Glucose/Weight Basal Blood Glucose Levels Body Weight 600 40 soo LA B 30 400 es a3 § ; € = = 300 —— $20 3 a. 200 10 100 5 ° ° 223 4 5 6 7 & 9 10.11 42.13 —eHcontral 20203 4 5 6 7 8 8 40 4112 13 ~eXcontral ‘Weeks after transplantation — ‘Weeks after transplant seemed Fig. 7. (A) Glucos
Slide 17: Pre-Clinical — Trig/Chol Levels
mum Pre-Clinical — Trig/Chol Levels Trig—ctrl mg/dL Trig—tx mg/dL Chol-ctrl mg/dL Chol-tx mg/dL Baseline 1Mth 2Mth 3Mth Trig—ctrl mg/dt 115+16 147413 159421 165414 Trig — tx mg/dL 120+14 14215 13019 Aisne Chol— ctrl mg/dt 13616 151415 188426 224434 136424 126419 Chol-tx mg/dt 125412 130414 ™ Baselin
Slide 18: brtx-C Cosmetic Overview
uum DItx-C Cosmetic Overview ¢BRT has developed an adult stem cell-derived extract for incorporation in third parties’ beauty care products — Potential use gs a primary ingredient for a new generation of “anti-aging beauty care products — Potent non-animal-based extract Per initial in vitro studies,
Slide 19: brtx-C Extract Impact
mae DItx-C Extract Impact Dermal Fibroblasts With Extract (-) lyophilized supernatant/Media (+) lyophilized supernatant/Media (based on initial in vitro studies) bi —
Slide 20: brtx-C Collagen/Fibronectin
% Change BR i=) 6 1 COLLAGEN 2.5 mg/ml 5 © Target @ brtx-c 10 250 200 50 mame DItx-C Collagen/Fibronectin © Target @ brtx-c FIBRONECTIN al 25 =: 10 mg/ml biorestorat\ve
Slide 21: Stem Pearls, LLC
mum otem Pearls®, LLC Wholly-owned subsidiary of BRT Plant-derived stem cell cosmetic products Formulation developed from stem cells of rare-variety 18" century Swiss apple Products for sale at stermpear|s.com Intent to offer products directly and through distributors to retail, spa and medical loca
Slide 22: Our Pipeline
Our Pipeline ee Commercial Programs Preclinical Phasel Phasell Phaselll Ready Core Program: brtx-C Cosmetic (No FDA Clinical Pathway Required) brtxDISC™ Potential to bypass ThermoStem® Non-Core Program: Stem Pearls® (No FDA Clinical Pathway Required) (cosmetic products using plant stem cells) reston
Slide 23: BRT Near-Term Goals
gauss BRT Near-Term Goals e 2H 2013 — Establish commercial agreements for brtx-C Cosmetic — File IND/IDE for brtxDISC™ program — File additional intellectual property — Submit pre-clinical results for ThermoStem® for peer- reviewed publication — File additional NIH grants e 2014 — Revenue from brtx-
Slide 24: Thank You
pionestoreitins therapies THANK YOU BIORESTORATIVE THERAPIES, INC. OTCBB: BRTX biorestorative.com bi orestordire
BioRestorative Therapies — Marcum Microcap Conference 2013 on 6ix